SRPU ETF

SRPU ETF
$5.88
See how much of SRPU you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Mar 31, 2026

Net Assets
$3M
Expense Ratio
1.30%
Dividend Yield (Current)
-
Holdings
4
Inception Date
Oct 22, 2025
Fund Family
Tradr ETFs
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD-49.31%

Asset Allocation

Cash: 110.58%
See how much of SRPU you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
-Deutsche Bank Securities 09/18/2024200.00%
-U.S. Treasury 3.00% 2/15/2048110.58%
-Gnma2 30Yr 5.5 05/20/2054-32.01%
-Cfd Sarepta Therapeutics Inc-178.57%
Top 10 Concentration: 100.00%Report Date: Mar 31, 2026
Download all 4 holdings for SRPU
CSV export with sector, industry & share changes
Get CSV

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This ETF
PRO
Peer Avg
PRO

SRPU ETF Overview

SRPU ETF (Tradr 2X Long SRPT Daily ETF) is managed by Tradr ETFs with $2.7M in net assets. SRPU expense ratio is 1.30%, holding 4 positions across various sectors. Inception date: 2025-10-22.

SRPU performance shows a YTD return of -49.31%..

SRPU top holdings include Deutsche Bank Securities 09/18/2024 (200.0%), U.S. Treasury 3.00% 2/15/2048 (110.6%), Gnma2 30Yr 5.5 05/20/2054 (-32.0%), Cfd Sarepta Therapeutics Inc (-178.6%). Go to all SRPU holdings, SRPU sectors, or SRPU dividends.

SRPU can be compared against other funds. Use SRPU overlap to find shared positions, or SRPU vs another fund for a side-by-side view. SRPU alternatives are available via the screener, along with tax-loss harvesting opportunities.

1 Month
-29.76%
YTD
-49.31%
1 Year
N/A
3 Year
N/A

Top 10 Holdings (net long exposure of 100% (≈5x))

#TickerNameSectorWeight
1-Deutsche Bank Securities 09/18/2024Other200.00%
2-U.S. Treasury 3.00% 2/15/2048Other110.58%
3-Gnma2 30Yr 5.5 05/20/2054Other-32.01%
4-Cfd Sarepta Therapeutics IncOther-178.57%